TacticScaleWhat Akeso Does & How It Makes Money (9926.HK)
Updated October 2026 · reflects Akeso's latest reported financials
Chinese biotech developing antibody drugs for cancer and immune diseases. Akeso earns revenue by manufacturing and selling approved antibody drugs, and it funds a pipeline of drug candidates in development that could bring in future sales.
How Akeso makes money
Akeso earns revenue by manufacturing and selling approved antibody drugs, and it funds a pipeline of drug candidates in development that could bring in future sales.
What Akeso does
Akeso, Inc. is a biopharmaceutical company founded in 2012 and based in Zhongshan, China. It researches, develops, manufactures and commercializes antibody drugs, with a strong focus on cancer immunotherapy. Its lead assets are bispecific antibodies: AK104, which targets PD-1 and CTLA-4 for cervical, gastric, lung and liver cancers, and AK112, which targets PD-1 and VEGF for lung, biliary tract, head and neck, breast, colorectal and pancreatic cancers. Other oncology programs include the PD-1 antibodies penpulimab and AK109, the PD-L1 antibody tagitanlimab, and the CD47 antibody AK117 for blood cancers. Akeso is also developing drugs outside oncology. These include AK102 (PCSK9) for high cholesterol and mixed hyperlipidemia, AK101 (IL-12/IL-23) for psoriasis and ulcerative colitis, AK111 (IL-17) for psoriasis and ankylosing spondylitis, and AK120 (IL-4R) for atopic dermatitis.
Products & services
- AK104 (PD-1/CTLA-4 bispecific)
- AK112 (PD-1/VEGF bispecific)
- Penpulimab (PD-1)
- AK117 (CD47 antibody)
- AK102 (PCSK9 antibody)
- AK101 (IL-12/IL-23 antibody)
What is Akeso worth?
A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.
We show a fair value only when the method is trustworthy. See Akeso on TacticScale →
Related companies
Bio-Thera Solutions (688177.SS) · Anhui Anke Biotechnology (300009.SZ) · Beijing Aosaikang Pharmaceutical (002755.SZ) · Xencor (XNCR)